ADIL vs. INAB, APRE, OKUR, SNTI, MIRA, LPCN, BCAB, MEIP, MRKR, and CARM
Should you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include IN8bio (INAB), Aprea Therapeutics (APRE), OnKure Therapeutics (OKUR), Senti Biosciences (SNTI), MIRA Pharmaceuticals (MIRA), Lipocine (LPCN), BioAtla (BCAB), MEI Pharma (MEIP), Marker Therapeutics (MRKR), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical products" industry.
Adial Pharmaceuticals vs.
Adial Pharmaceuticals (NASDAQ:ADIL) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk, profitability and community ranking.
Adial Pharmaceuticals has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500.
16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 5.2% of Adial Pharmaceuticals shares are owned by company insiders. Comparatively, 15.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Adial Pharmaceuticals' return on equity of -168.25% beat IN8bio's return on equity.
Adial Pharmaceuticals currently has a consensus price target of $8.00, indicating a potential upside of 917.81%. IN8bio has a consensus price target of $7.75, indicating a potential upside of 2,754.51%. Given IN8bio's higher probable upside, analysts clearly believe IN8bio is more favorable than Adial Pharmaceuticals.
Adial Pharmaceuticals received 85 more outperform votes than IN8bio when rated by MarketBeat users. However, 73.53% of users gave IN8bio an outperform vote while only 58.51% of users gave Adial Pharmaceuticals an outperform vote.
In the previous week, IN8bio had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 3 mentions for IN8bio and 2 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 0.40 beat IN8bio's score of 0.13 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.
Summary
Adial Pharmaceuticals and IN8bio tied by winning 7 of the 14 factors compared between the two stocks.
Get Adial Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adial Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ADIL) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ADIL Stock Alerts